{"preliminary_commentary":{"by_channel":{"bluesky_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"PAM","nct_id":"NCT04262089","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pam-nct04262089. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PAM","arms":[{"description":"primary dMMR uterine cancer patients","label":"primary dMMR uterine cancer patients","type":"EXPERIMENTAL"},{"description":"primary POLE-EDM uterine cancer patients","label":"primary POLE-EDM uterine cancer patients","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2023-11-01","type":"ACTUAL"},"conditions":["Uterine Cancer"],"enrollment":{"count":10,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab (Keytruda)","otherNames":[],"type":"DRUG"}],"last_update":"2023-12-05","lead_sponsor":"University Medical Center Groningen","official_title":"Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2023-04-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"The primary objective is to characterize pathologic responses (necrosis/viable tumor cells) in uterine cancer patients treated with neo-adjuvant pembrolizumab","timeFrame":"Tumor tissue is collected during standard of care hysterectomy (up to 6-10 weeks after baseline)"},{"measure":"The primary objective is to characterize pathologic responses (Degree of immune infiltration) in uterine cancer patients treated with neo-adjuvant pembrolizumab","timeFrame":"Tumor tissue is collected during standard of care hysterectomy (week 6-10 after baseline)"},{"measure":"The primary objective is to characterize pathologic responses (Degrees of inflammation, fibrosis, and mucin) in uterine cancer patients treated with neo-adjuvant pembrolizumab","timeFrame":"Tumor tissue is collected during standard of care hysterectomy (week 6-10 after baseline)"}],"references":[{"citation":"Eerkens AL, Brummel K, Vledder A, Paijens ST, Requesens M, Loiero D, van Rooij N, Plat A, Haan FJ, Klok P, Yigit R, Roelofsen T, de Lange NM, Klomp R, Church D, Ter Elst A, Wardenaar R, Spierings D, Foijer F, Koelzer VH, Bosse T, Bart J, Jalving M, Reyners AKL, de Bruyn M, Nijman HW. Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study. Nat Commun. 2024 Sep 3;15(1):7695. doi: 10.1038/s41467-024-52098-8.","pmid":"39227583","type":"DERIVED"}],"start_date":{"date":"2020-11-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study","url":"https://clinicaltrials.gov/study/NCT04262089"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pam-nct04262089"}